Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Verastem, Inc. (VSTM) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2023 8-K Quarterly results
08/10/2023 SC 13G/A BAKER BROS. ADVISORS LP reports a 0% stake in Verastem, Inc.
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/04/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Payments Subject to Section 409A"
07/27/2023 SC 13G Soleus Capital Master Fund, L.P. reports a 5.1% stake in Verastem, Inc.
07/12/2023 8-K Quarterly results
06/12/2023 SC 13G/A BAKER BROS. ADVISORS LP reports a 8% stake in Verastem, Inc.
06/08/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "LGSOC NSCLC 1H2022 RAMP 201"
06/05/2023 SC 13G VIKING GLOBAL INVESTORS LP reports a 7.9% stake in Verastem, Inc.
05/31/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED OF VERASTEM, INC.",
"Verastem Oncology Announces Reverse Stock Split"
05/25/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
05/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/25/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/24/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
04/18/2023 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
04/05/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/27/2023 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ...
03/24/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/23/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
03/14/2023 10-K Annual Report for the period ended December 31, 2022
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
02/14/2023 SC 13G ORBIMED ADVISORS LLC reports a 7.9% stake in Verastem, Inc.
02/14/2023 SC 13G/A BAKER BROS. ADVISORS LP reports a 13.5% stake in Verastem, Inc.
02/02/2023 8-K Quarterly results
01/25/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...
Docs: "VERASTEM, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF THE SERIES B CONVERTIBLE PREFERRED STOCK",
"SECURITIES PURCHASE AGREEMENT"
01/24/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "LGSOC Program Update January 24, 2023",
"Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer",
"Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Preferred Convertible Stock BOSTON – – Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has entered into a definitive agreement to sell approximately 2.1 million shares of its Series B Convertible Preferred Stock to affiliates of BVF Partners L.P. in a private placement to raise aggregate gross proceeds of up to approximately $60 million in two tranches, before deducting fees to the placement agent and other estimated offering expenses payable by the Company. The initial tranche, consisting of 1.2 million shares of Preferred Stock for gross proceeds of approximately $30 million, representing a purchase price per share equ..."
12/15/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
11/07/2022 8-K Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial ...
Docs: "VERASTEM, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK",
"Letter re: 3 Exchange Agreement"
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/20/2022 8-K Quarterly results
10/04/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
09/30/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy